Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study

JAAD Int. 2022 Oct 30:10:46-47. doi: 10.1016/j.jdin.2022.10.004. eCollection 2023 Mar.

Authors

Ahmad Shahin¹, Monica Janeczek², Richard Butterfield³, Puneet Bhullar^{1

2}, Blake Boudreaux², Thai Ho⁴, Aaron Mangold²

Affiliations

¹ Mayo Clinic Alix School of Medicine, Scottsdale, Arizona.
² Department of Dermatology, Mayo Clinic, Scottsdale, Arizona.
³ Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, Arizona.
⁴ Division of Medical Oncology, Mayo Clinic, Phoenix, Arizona.

No abstract available

Keywords: drug eruption; drug reaction; enfortumab vedotin; medical dermatology; oncologic therapy; oncology.